argenx SE (BVMF:A1RG34)

Brazil flag Brazil · Delayed Price · Currency is BRL
200.20
+4.60 (2.35%)
At close: Nov 26, 2025
41.03%
Market Cap302.48B
Revenue (ttm)19.63B
Net Income (ttm)8.17B
Shares Outn/a
EPS (ttm)124.02
PE Ratio37.02
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2
Average Volume324
Open200.20
Previous Close195.60
Day's Range200.20 - 200.20
52-Week Range116.88 - 200.20
Beta-0.11
RSI71.13
Earnings DateFeb 26, 2026

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 1,599
Stock Exchange Brazil Stock Exchange
Ticker Symbol A1RG34
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.